Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing

Korro Bio stock plummeted Thursday after its RNA-editing drug failed to pass muster in patients with a rare lung and liver disease.

Investors Business Daily • Nov 13, 2025

Korro Bio Early Trial Results Fall Short; Stock Hits New Low

Korro Bio, Inc. (NASDAQ: KRRO) stock is sinking on Thursday with a session volume of 6.68 million compared to the average volume of 1.42 million, as per data from Benzinga Pro.

Benzinga • Nov 13, 2025

This biotech is halting its work with Novo Nordisk and laying off more people

Korro is the latest to rethink its ties with the Danish pharma company.

Market Watch • Nov 12, 2025

Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs

CAMBRIDGE, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- — KRRO-110 produced functional protein in Alpha-1 Antitrypsin Deficiency (AATD) patients     — KRRO-110 did not reach projected levels of functional protein following a single administration      — Pivoting to GalNAc delivery for patients with AATD; development candidate nomination expected in the first half of 2026     — Nominated KRRO-121, designed to create a de novo protein variant to activate a biological pathway for patients with hyperammonemia     — Reports third quarter 2025 financial results; ended third quarter 2025 with $102.5 million in cash, cash equivalents and marketable securities; extending cash runway into second half of 2027 by implementing a strategic restructuring     CAMBRIDGE, Mass.

GlobeNewsWire • Nov 12, 2025

Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates

Korro Bio, Inc. (KRRO) came out with a quarterly loss of $1.92 per share versus the Zacks Consensus Estimate of a loss of $2.61. This compares to a loss of $2.26 per share a year ago.

Zacks Investment Research • Nov 12, 2025

Korro to Participate in Upcoming Investor and Scientific Conferences

CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor and scientific conferences for the month of September:

GlobeNewsWire • Sep 2, 2025

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

— Interim readout from Phase 1/2a REWRITE clinical trial of KRRO-110 on track for the second half of 2025 — Completed dosing of over 80% of planned REWRITE healthy volunteers across multiple single ascending dose (SAD)  cohorts with no treatment emergent serious adverse events (SAEs) or dose limiting toxicities observed — European Medicines Agency (EMA) granted Orphan Drug Designation to KRRO-110 for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) — Development candidate for Korro's rare metabolic disorder program will be announced by end of 2025 — Ended second quarter 2025 with $119.6 million in cash, cash equivalents and marketable securities   CAMBRIDGE, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the second quarter of 2025 and provided a business update.

GlobeNewsWire • Aug 12, 2025

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today that it has been granted orphan drug designation by the European Medicines Agency (EMA) Committee, who adopted a positive opinion on KRRO-110, Korro's investigational medicine for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).

GlobeNewsWire • Jul 21, 2025

Korro to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that members of management will participate in the following upcoming investor conferences: 2025 RBC Capital Markets Global Healthcare Conference Ram Aiyar, Ph.D.

GlobeNewsWire • May 14, 2025

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

CAMBRIDGE, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results for the first quarter of 2025 and provided a business update.

GlobeNewsWire • May 7, 2025